bcl-2与乳腺癌耐药蛋白基因在弥漫大B细胞淋巴瘤中表达的意义

Clinical significance of expressions of bcl-2 and BCRP in diffuse large B cell lymphoma

目的研究bcl-2和乳腺癌耐药蛋白（BCRP）基因在非霍奇金淋巴瘤（NHL）中的表达及其相关性。方法对初治弥漫大B细胞淋巴瘤（DLBCL）患者（40例）淋巴结组织液，采用流式细胞术（FCM）及反转录聚合酶链反应（RT—PCR）技术定量检测其BCRPmRNA的表达，同时将患者标本常规石蜡包埋、HE染色和链霉菌素生物素技术（LSAB）免疫组织化学法标记bcl-2蛋白表达。结果40例DLBLC患者的bcl-2与BCRP的阳性表达率分别为60．0％（24／40），37．5％（15／40），不同临床分期的DLBCL患者，BCRP阳性表达率差异有统计学意义（χ2=6．0606，P〈0．05）。bcl-2、BCRP表达阳性组有效率低于表达阴性组，差异有统计学意义（χ2=5．7618，P〈0．05；χ2=6．5541，P〈0．05）；bcl-2和BCRP表达均阳性与均阴性患者的疗效比较，差异无统计学意义（χ2=2．0263，P〉0．05）。结论BCRP可能在DLBCL的原发多药耐药中发挥重要作用，并有助于化疗疗效的评估及提示疾病转归；bcl-2在DLBCL中的表达对肿瘤恶性程度及预后的判断均有一定意义；联合检测bcl=2和BCRP基因对评价DLBCL预后有较大意义。

Objective To explore the expression of b-cell lymphoma/leukemia-2 （bcl-2） and breast cancer drug-resistant protein （BCRP） in diffuse large B cell lymphoma （DLBCL） and their correlation. Methods Using flow cytometry （FCM） and semi-quantitative reverse transcription polymerase chain reaction （RT-PCR） assay the expressions of BCRP gene was analysed in 40 DLBCL samples, bcl-2 protein were measured by immunohistoehemistry on paraffin-embedded slices in 40 cases of DLBCL. Results The positive expression rate of bcl-2 and BCRP protein were 60,0 % （24/40） and 37.5 % （15/40） in 40 patients with DLBCL respectively. There was significant differences between positive group and negative groups （χ2= 5.7618, P 〈0.05; ）χ2 = 6.5541, P 〈0.05）. There was no significant correlation between Bcl-2 and BCRP gene in effective treatment group and therapies group or progress group （χ2 = 2.0263, P 〉0.05）. Conclusion BCRP may play an important role in DLBCL primay much medicine drug-resistant, thus it may be a useful prediction of chemotherapeutic treatment and risk of relapse. The level bcl-2 expression was closely related with the grade of malignancy and the prognosis of DLBCL. There was no significant correlation between bcl-2 and BCRP gene. The detection of bcl-2 and BCRP gene played an important role in evaluating DLBCL outcome.